You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業(1875.HK)2024年中期業績發佈會
格隆匯 08-08 10:22

東曜藥業(1875.HK)將於2024年8月14日14:30在香港舉辦2024年中期業績發佈會,歡迎投資者預約參會。

東曜藥業有限公司(簡稱"東曜藥業")於2019年在香港聯交所主板上市,從事抗體及ADC藥物研發10餘年,自2020年全面轉型生物藥CDMO後,目前已搭建國內高規格的,集抗體、ADC原液及製劑於一體的"一地化·端到端"商業化生產線,並將持續打造前沿ADC CDMO技術平台。

據公司2024年一季度公吿顯示:得益於成功的戰略轉型,公司業績奪目。營業收入自2021年Q1的1458.4萬元快速增長至2024年Q1的2.23億元,複合年增長率達到了148%,遠高於同行平均增速。同時,公司正式實現扭虧為盈,淨利潤約740.9萬元。

*2022 Q1淨虧損包含授權金收入的大幅正向影響

繼2024年一季度公吿後,公司管理層擬於8月14日前往香港發佈中期業績,屆時將與廣大投資者們共同探討公司最新業績和未來展望。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account